Does the media prefer ONT or PRTC?

In the previous week, Oxford Nanopore Technologies had 7 more articles in the media than PureTech Health. MarketBeat recorded 8 mentions for Oxford Nanopore Technologies and 1 mentions for PureTech Health. Oxford Nanopore Technologies' average media sentiment score of 0.24 beat PureTech Health's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Nanopore Technologies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ERGO or PRTC?

PureTech Health has a consensus price target of GBX 508, suggesting a potential upside of 302.54%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Ergomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings and valuation, ERGO or PRTC?

Ergomed has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ergomed £152.09M 0.00 £15M £0.29 N/A PureTech Health £4.66M 65.94 -£91.86M -£46.00 N/A

Is ERGO or PRTC more profitable?

Ergomed has a net margin of 9.87% compared to PureTech Health's net margin of -2,355.32%. Ergomed's return on equity of 18.08% beat PureTech Health's return on equity. Company Net Margins Return on Equity Return on Assets Ergomed 9.87% 18.08% 10.16% PureTech Health -2,355.32% -31.98% -13.39%

Do analysts prefer SLN or PRTC?

PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 302.54%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media prefer AVCT or PRTC?

In the previous week, Avacta Group and Avacta Group both had 1 articles in the media. Avacta Group's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

PureTech Health (PRTC) Competitors

GBX 126.20 +1.20 (+0.96%)

As of 11:54 AM Eastern

Compare

PRTC vs. ONT, OXB, ERGO, SLN, and AVCT

Should you buy PureTech Health stock or one of its competitors? MarketBeat compares PureTech Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PureTech Health include Oxford Nanopore Technologies (ONT), Oxford Biomedica (OXB), Ergomed (ERGO), Silence Therapeutics (SLN), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.

How does PureTech Health compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Oxford Nanopore Technologies currently has a consensus target price of GBX 212.60, indicating a potential upside of 92.05%. PureTech Health has a consensus target price of GBX 508, indicating a potential upside of 302.54%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Oxford Nanopore Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

PureTech Health has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	4.82	-£175.21M	-£15.10	N/A
PureTech Health	£4.66M	65.94	-£91.86M	-£46.00	N/A

In the previous week, Oxford Nanopore Technologies had 7 more articles in the media than PureTech Health. MarketBeat recorded 8 mentions for Oxford Nanopore Technologies and 1 mentions for PureTech Health. Oxford Nanopore Technologies' average media sentiment score of 0.24 beat PureTech Health's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Nanopore Technologies	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

16.4% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 33.5% of PureTech Health shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Comparatively, 13.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oxford Nanopore Technologies has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, PureTech Health has a beta of 0.793, indicating that its share price is 21% less volatile than the broader market.

Oxford Nanopore Technologies has a net margin of -64.85% compared to PureTech Health's net margin of -2,355.32%. Oxford Nanopore Technologies' return on equity of -29.43% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Summary

Oxford Nanopore Technologies and PureTech Health tied by winning 8 of the 16 factors compared between the two stocks.

How does PureTech Health compare to Oxford Biomedica?

PureTech Health (LON:PRTC) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

PureTech Health currently has a consensus price target of GBX 508, indicating a potential upside of 302.54%. Oxford Biomedica has a consensus price target of GBX 633.38, indicating a potential upside of 5.00%. Given PureTech Health's higher probable upside, equities analysts plainly believe PureTech Health is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, PureTech Health had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Oxford Biomedica. PureTech Health's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Oxford Biomedica	Neutral

33.5% of PureTech Health shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 13.3% of PureTech Health shares are held by insiders. Comparatively, 34.8% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PureTech Health has a beta of 0.793, indicating that its share price is 21% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

PureTech Health has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	65.94	-£91.86M	-£46.00	N/A
Oxford Biomedica	£168.74M	4.33	-£143.51M	-£26.92	N/A

Oxford Biomedica has a net margin of -17.85% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Summary

PureTech Health and Oxford Biomedica tied by winning 7 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Ergomed?

Ergomed (LON:ERGO) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Ergomed has a net margin of 9.87% compared to PureTech Health's net margin of -2,355.32%. Ergomed's return on equity of 18.08% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ergomed	9.87%	18.08%	10.16%
PureTech Health	-2,355.32%	-31.98%	-13.39%

71.1% of Ergomed shares are owned by institutional investors. Comparatively, 33.5% of PureTech Health shares are owned by institutional investors. 18.2% of Ergomed shares are owned by insiders. Comparatively, 13.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ergomed has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ergomed	£152.09M	0.00	£15M	£0.29	N/A
PureTech Health	£4.66M	65.94	-£91.86M	-£46.00	N/A

In the previous week, PureTech Health had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Ergomed. Ergomed's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Overall Sentiment
Ergomed	Neutral
PureTech Health	Neutral

PureTech Health has a consensus price target of GBX 508, suggesting a potential upside of 302.54%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, PureTech Health has a beta of 0.793, meaning that its share price is 21% less volatile than the broader market.

Summary

Ergomed beats PureTech Health on 9 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

In the previous week, PureTech Health had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Overall Sentiment
Silence Therapeutics	Neutral
PureTech Health	Neutral

33.5% of PureTech Health shares are held by institutional investors. 13.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 302.54%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Silence Therapeutics has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Silence Therapeutics' return on equity of 0.00% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
PureTech Health	-2,355.32%	-31.98%	-13.39%

Silence Therapeutics has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
PureTech Health	£4.66M	65.94	-£91.86M	-£46.00	N/A

Summary

PureTech Health beats Silence Therapeutics on 8 of the 12 factors compared between the two stocks.

How does PureTech Health compare to Avacta Group?

Avacta Group (LON:AVCT) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

PureTech Health has a net margin of -2,355.32% compared to Avacta Group's net margin of -33,961.06%. PureTech Health's return on equity of -31.98% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Avacta Group has higher earnings, but lower revenue than PureTech Health. Avacta Group is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,778.12	-£30.08M	-£9.66	N/A
PureTech Health	£4.66M	65.94	-£91.86M	-£46.00	N/A

In the previous week, Avacta Group and Avacta Group both had 1 articles in the media. Avacta Group's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avacta Group currently has a consensus target price of GBX 99, indicating a potential upside of 47.76%. PureTech Health has a consensus target price of GBX 508, indicating a potential upside of 302.54%. Given PureTech Health's higher probable upside, analysts clearly believe PureTech Health is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

3.1% of Avacta Group shares are held by institutional investors. Comparatively, 33.5% of PureTech Health shares are held by institutional investors. 47.7% of Avacta Group shares are held by company insiders. Comparatively, 13.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Avacta Group has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.793, indicating that its share price is 21% less volatile than the broader market.

Summary

PureTech Health beats Avacta Group on 7 of the 12 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£307.19M	£514.53M	£6.80B	£2.79B
Dividend Yield	N/A	3.90%	2.67%	6.16%
P/E Ratio	-2.74	3.15	27.03	368.24
Price / Sales	65.94	6,249.80	515.69	84,392.85
Price / Cash	2.14	13.13	26.68	27.89
Price / Book	1.11	87.81	10.67	7.59
Net Income	-£91.86M	-£96.07M	£3.59B	£5.89B
7 Day Performance	1.02%	-0.91%	-0.60%	0.05%
1 Month Performance	-3.96%	0.92%	1.63%	-0.67%
1 Year Performance	-8.68%	58.45%	25.09%	62.47%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	2.3502 of 5 stars	GBX 126.20 +1.0%	GBX 508 +302.5%	-8.4%	£307.19M	£4.66M	N/A	300	News Coverage Positive News Gap Up
ONT Oxford Nanopore Technologies	3.3453 of 5 stars	GBX 112.30 -3.1%	GBX 212.60 +89.3%	-26.1%	£1.10B	£223.90M	N/A	1,281	Analyst Downgrade
OXB Oxford Biomedica	0.95 of 5 stars	GBX 646 -0.5%	GBX 633.38 -2.0%	+64.3%	£781.90M	£168.74M	N/A	891
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:PRTC) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. ONT, OXB, ERGO, SLN, and AVCT

How does PureTech Health compare to Oxford Nanopore Technologies?

Summary

How does PureTech Health compare to Oxford Biomedica?

Summary

How does PureTech Health compare to Ergomed?

Summary

How does PureTech Health compare to Silence Therapeutics?

Summary

How does PureTech Health compare to Avacta Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. ONT, OXB, ERGO, SLN, and AVCT

How does PureTech Health compare to Oxford Nanopore Technologies?

Do analysts prefer ONT or PRTC?

Which has better earnings & valuation, ONT or PRTC?

Does the media prefer ONT or PRTC?

Do insiders & institutionals have more ownership in ONT or PRTC?

Which has more volatility & risk, ONT or PRTC?

Is ONT or PRTC more profitable?

Summary

How does PureTech Health compare to Oxford Biomedica?

Do analysts rate PRTC or OXB?

Does the media favor PRTC or OXB?

Do insiders & institutionals believe in PRTC or OXB?

Which has more risk & volatility, PRTC or OXB?

Which has stronger valuation & earnings, PRTC or OXB?

Is PRTC or OXB more profitable?

Summary

How does PureTech Health compare to Ergomed?

Is ERGO or PRTC more profitable?

Do institutionals & insiders hold more shares of ERGO or PRTC?

Which has stronger earnings and valuation, ERGO or PRTC?

Does the media prefer ERGO or PRTC?

Do analysts rate ERGO or PRTC?

Which has more volatility and risk, ERGO or PRTC?

Summary

How does PureTech Health compare to Silence Therapeutics?

Does the media favor SLN or PRTC?

Do insiders and institutionals believe in SLN or PRTC?

Do analysts prefer SLN or PRTC?

Is SLN or PRTC more profitable?

Which has better earnings & valuation, SLN or PRTC?

Summary

How does PureTech Health compare to Avacta Group?

Is AVCT or PRTC more profitable?

Which has higher valuation & earnings, AVCT or PRTC?

Does the media prefer AVCT or PRTC?

Do analysts prefer AVCT or PRTC?

Do institutionals & insiders believe in AVCT or PRTC?

Which has more volatility & risk, AVCT or PRTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools